Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.